STRATEGIC DIVISION

Advanced Therapeutics
for Complex Diseases

Discovering, developing, and delivering next-generation biologics that redefine treatment standards across oncology, immunology, neurology, and rare diseases.

📅 Fiscal Year 2026 🔬 14 Approved Programs 🌍 Global Distribution

Division Overview

01 / Strategy & Focus

Aevum Zenth Biologics operates at the intersection of computational biology, synthetic engineering, and advanced clinical development. Our platform-driven approach accelerates the translation of novel molecular targets into safe, scalable, and clinically transformative therapies.

Core therapeutic modalities include monoclonal antibodies, bispecific constructs, chimeric antigen receptor (CAR) cell therapies, adeno-associated viral (AAV) gene vectors, and next-generation recombinant proteins.

14
Approved Products
38
Active Clinical Trials
9
GMP Facilities
$2.1B
Annual R&D Spend

Product Portfolio

02 / Commercial Programs
Zenthra™ Approved
Monoclonal Antibody (IgG1)
Indication: NSCLC, Melanoma, CRC
Target: PD-1 / TGF-β dual blockade
Celvira® Approved
Autologous CAR-T Cell Therapy
Indication: Relapsed/Refractory CLL, NHL
Target: CD19 / CD22 bispecific CAR
Oncorex® Phase III
AAV Gene Therapy Vector
Indication: Spinal Muscular Atrophy, AMD
Target: SMN1 replacement, RPE65 restoration
Vaxion™ Platform Phase II
LNP-Encapsulated mRNA
Indication: Therapeutic Cancer Vaccines
Target: Neoantigen multi-epitope cocktails
Enzyra® Phase II
Recombinant Enzyme Replacement
Indication: Lysosomal Storage Disorders
Target: PEGylated alpha-galactosidase A
NeuroZenth™ Preclinical
Bispecific Antibody
Indication: Alzheimer’s Disease, ALS
Target: Aβ42 / pTau microtubule stabilization

Clinical Development Pipeline

03 / Stage Progression
Preclinical
Phase I
Phase II
Phase III
Regulatory

* Each dot represents an active program. Color indicates current development stage. Programs advance sequentially based on efficacy, safety, and manufacturing readiness.

Manufacturing & Quality

04 / Operational Excellence
🧬

Continuous Bioprocessing

Perfusion and fed-batch platforms enabling high-titer monoclonal antibody production with 40% reduced footprint and 2.3x faster campaign turnaround.

🏭

Single-Use & Disposable Systems

Validated closed-system manufacturing for cell and gene therapies, minimizing cross-contamination risk and accelerating campaign changeovers.

🔍

AI-Driven QC & PAT

Process Analytical Technology integrated with machine learning models for real-time viral clearance validation, host cell protein tracking, and lot release.

🌐

Global CDMO Network

Strategic partnerships with tier-1 contract development and manufacturing organizations across North America, EU, and APAC for capacity scaling.

FDA cGMP EMA GMP PMDA Compliance WHO Prequalification ISO 13485

Institutional & Scientific Contact

05 / Partnership & Access

Scientific Affairs

Clinical data requests, investigator-initiated trials, and medical information inquiries.

scientific@biologics.aevumzenth.com

Commercial Partnerships

Co-development, licensing, distribution agreements, and health system integrations.

partnerships@biologics.aevumzenth.com

Investor Relations

Divisional financials, pipeline valuation models, and ESG sustainability reporting.

ir@biologics.aevumzenth.com